Does intermittent fasting help your gut health?
Intermittent fasting likely improves your gut flora and gut barrier in the short term, but it remains unclear whether those effects persist once you stop. People who already benefit from IF for weight or blood sugar are probably picking up a gut benefit along the way.
Intermittent fasting measurably changes the composition of your gut flora. Across multiple studies, the quantities of certain bacterial strains shift, with some beneficial bacterial groups increasing. A systematic review found that the numbers of an average of 16 bacterial genera changed significantly during an IF period.
Things become more concrete in a randomised study involving people with metabolic syndrome: after 8 weeks of IF, the production of short-chain fatty acids (fatty acids that nourish the gut wall and support the immune system) increased, and the level of bacterial inflammatory substances in the blood decreased. The latter may indicate a stronger gut barrier. These are real human results, but they come from a single study in a specific group; whether this also applies to people without metabolic problems has not yet been demonstrated.
A separate study combined IF with additional protein intake and compared that with calorie restriction alone. The IF-plus-protein group fared better on gut symptoms and had more of a bacterial family associated with a healthier metabolism. However, that study includes only 41 participants and was funded by a commercial party, which makes the results less independent.
The biggest caveat is the durability of the effects. A systematic review emphasises that virtually all studies are short, and that the microbiome changes in some participants simply reverse once they stop the diet. Whether IF structurally changes anything about your gut health in the long term is not yet known. The evidence on long-term effects is insufficient.
Scientific review studies do regard the gut microbiome as a likely link between IF and broader health effects on metabolism and inflammation. But that is a hypothesis with growing supporting evidence, not a proven cause-and-effect chain.
Based on multiple systematic reviews, an RCT in metabolic syndrome, a small commercially funded RCT (n=41), and broad review studies. The human studies are relatively short (8 weeks) and vary considerably in population and method.